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SUMMARY
Endothelial progenitor cell (EPC) nomenclature remains ambiguous and there is a general lack of concordance in the stem cell ﬁeld
with many distinct cell subtypes continually grouped under the term “EPC.” It would be highly advantageous to agree on standards to
conﬁrm an endothelial progenitor phenotype and this should include detailed immunophenotyping, potency assays, and clear separa-
tion from hematopoietic angiogenic cells which are not endothelial progenitors. In this review, we seek to discourage the indiscrimi-
nate use of “EPCs,” and instead propose precise terminology based on deﬁning cellular phenotype and function. Endothelial colony
forming cells and myeloid angiogenic cells are examples of two distinct and well-deﬁned cell types that have been considered EPCs
because they both promote vascular repair, albeit by completely different mechanisms of action. It is acknowledged that scientiﬁc
nomenclature should be a dynamic process driven by technological and conceptual advances; ergo the ongoing “EPC” nomenclature
ought not to be permanent and should become more precise in the light of strong scientiﬁc evidence. This is especially important as
these cells become recognized for their role in vascular repair in health and disease and, in some cases, progress toward use in cell
therapy. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1316–1320
SIGNIFICANCE STATEMENT
There is need for a cytotherapy to facilitate new blood vessel formation in damaged organs, which is highly relevant for ischemic dis-
eases and three-dimensional tissue engineering. Therefore, there has been increased interest in identifying endothelial progenitors as
the “building blocks” of these vascular units. Unfortunately, as the research field has expanded, nomenclature relating to these cells
has become increasingly complex and does not always align with the latest scientific evidence. Ensuing confusion around endothelial
progenitor cell identity and function has sometimes diminished confidence in the field and the intent of this article is to raise concerns
on current standard practices and propose alternative, more accurate, terminology.
AMBIGUITY IN CURRENT DEFINITION FOR ENDOTHELIAL
PROGENITORS
Endothelial progenitor cells (EPCs) have been typically deﬁned as
cells that are able to differentiate into endothelial cells and con-
tribute to the formation of new blood vessels.While this theoreti-
cal deﬁnition remains broadly correct, it fails to align precisely
with the current scientiﬁc evidence and this has allowed a wide
variety of different cell types to be named and used as EPCs [1].
Some researchers have come to consider EPC as a highly hetero-
geneous population and because published studies cannot be eas-
ily compared, this has signiﬁcantly hampered scientiﬁc advances
in the ﬁeld and clinical translation. Moreover, this has resulted in
conﬂicting results reporting both incorporation [2] and lack of
incorporation [3] into host vasculature, and created confusion
about the role of these cells in health and disease [4].
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PERSPECTIVES
Working deﬁnitions for EPCs have also been criticized for lack
of speciﬁcity. For example, the EPC phenotype in culture is fre-
quently deﬁned by the combination of CD31 (PECAM1) expres-
sion, AcLDL uptake, and lectin (UEA) binding. However, it has
been demonstrated that cultured hematopoietic cells can effec-
tively acquire an EPC phenotype by passive transfer of platelet
microparticles containing CD31 [5]. In addition, markers classically
associated with endothelium such as CD31 and vascular endothe-
lial growth factor receptor 2 (VEGFR2) are also expressed in some
monocyte subpopulations [6]. AcLDL uptake and lectin binding
are not speciﬁc to endothelial progenitors as they are convention-
ally used for characterization of both macrophages and mature
endothelial cells. These deﬁciencies in current practices highlight
a major issue: expression of CD31, uptake of acLDL, and lectin
binding are insufﬁcient to deﬁne an endothelial progenitor in
vitro. This confusion arose because initially “putative” endothelial
progenitors were isolated from circulating blood mononuclear
cells expressing CD34 and Flk-1, and identiﬁed in culture by
acLDL-DiI uptake and CD31 expression [7]. Advances in knowledge
and technology currently enable a more detailed and accurate
deﬁnition.
CONFUSING NOMENCLATURE
Since Asahara et al. coined the terminology “putative EPCs” in
1997 [7], various different names to describe endothelial pro-
genitors have entered the scientiﬁc literature causing consider-
able confusion in the ﬁeld. To facilitate understanding, it is
important to recognize that there are two distinct approaches
used for studying endothelial progenitors: (a) Flow cytometry-
based assays in blood samples; and (b) In vitro cell culture iso-
lation methodologies [8] (Fig. 1).
Using ﬂow cytometry, circulating EPCs are frequently quan-
tiﬁed as the percentage of mononuclear cells expressing CD34
and VEGFR2. Because CD341 VEGFR21 cells may also identify
circulating mature endothelial cells sloughed from vasculature,
some research groups have included CD133 as an additional
progenitor marker [9]. While enumeration of CD341 VEGFR21
cells appears to be a useful biomarker for cardiovascular risk
[10], the use of CD133 as an additional progenitor marker
remains controversial. There is evidence to demonstrate that
CD341 CD1331 cells give rise to endothelial cells [11]; how-
ever, there is also evidence to the contrary, demonstrating that
CD341 CD1331 VEGFR21 cells do not normally yield endo-
thelium but remain hematopoietic [12].
For EPCs isolated using cell culture methodologies, there is
now agreement that two different populations can be distin-
guished. Originally, these were known as early and late EPCs in
relation to their time of appearance in culture [13], although the
phenotype of these two cell populations is very different; one
being hematopoietic, and the other endothelial, respectively [14].
This led to a proposal to rename these cells as “hematopoietic
EPCs” and “nonhematopoietic EPCs” [15], based on the hypothe-
sis that hematopoietic EPCs will give rise to nonhematopoietic
EPCs and ultimately endothelial cells. Since the existence of an
“adult hemangioblast” has not been convincingly demonstrated,
we should avoid considering adult hematopoietic cells as endo-
thelial progenitors. Moreover, since the term hematopoietic EPCs
is based on unproven assumptions and creates confusion, it is our
recommendation that researchers in the ﬁeld avoid using this
term.
The name “circulating angiogenic cells” (CACs) is frequently
used to identify early EPCs [16]. This nomenclature assumes that
these cells circulate in blood, and while this is likely, currently
there is insufﬁcient proof to conﬁrm such “circulating” status in
vivo. In fact, it has been suggested that CACs might be generated
“in vitro” due to cell culture conditions that do not exist “in vivo.”
Therefore, we recommend referring to these cells as myeloid
angiogenic cells (MACs) to clarify both their lineage and function.
MACs are deﬁned as cultured cells derived from peripheral blood
mononuclear cells grown under endothelial cell culture condi-
tions, which are characterized by an immunophenotype depicted
as positive for CD45, CD14, CD31, and negative for CD146, CD133,
and Tie2 [17, 18]. MACs do not have capacity to become endothe-
lial cells, but promote angiogenesis through a paracrine mecha-
nism [19].
In culture, a second cell population can also be obtained and
the name “endothelial outgrowth cells” was used to identify
these late EPCs [20]. These cells are now more commonly known
as endothelial colony forming cells (ECFCs) and represent an
endothelial cell type with potent intrinsic angiogenic capacity,
capable of contributing to vascular repair of injured endothelium
as well as de novo blood vessel formation [21]. This vasculogenic
property is further enhanced by their role as trophic mediators
through release of paracrine factors [22].
There have been major controversies when trying to deﬁne
“bona ﬁde EPCs” and disparate results are difﬁcult to reconcile,
due to differences in compositions of cell populations used [23].
Most reports have tried to demonstrate the superiority of one cell
type versus another. We need to recognize that cell composition,
purity, and mechanisms of action differ greatly, which makes
meaningful comparisons difﬁcult. In addition, different cell types
Figure 1. Methodology used to study human endothelial progeni-
tors. Enumeration of EPCs circulating in blood is performed using
ﬂow cytometry. Cell culture technology consistently allows the isola-
tion of well-deﬁned cell populations with vasoreparative properties
such as ECFCs and MACs. ECFCs are fully committed to the endothe-
lial lineage while MACs exhibit a phenotype similar to M2 macro-
phages. 6¼ indicates that ECFCs and MACs represent highly distinct
cell populations evidenced by their immunophenotype and pro-
angiogenic mechanism of action. Abbreviations: ECFCs, endothelial
colony forming cells; EPC, endothelial progenitor cell; MACs, mye-
loid angiogenic cells; VEGFR2, vascular endothelial growth factor
receptor 2.
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may play dissimilar roles and there is evidence to suggest a syner-
gistic effect when distinct EPCs are used together [13]. To guide
scientists new to the complex ﬁeld of cells studied for vascular
regeneration, we have grouped the different names into two
main categories according to their hematopoietic (myeloid) or
endothelial lineage (Fig. 2).
REVISED TERMINOLOGY
It is widely appreciated that the current EPC nomenclature is inac-
curate and current standards were suggested over a decade ago
[24].While this was valuable in providing a starting framework for
understanding EPC biology, we feel it is now time to use the most
recent molecular and functional data to update terminology with
obvious beneﬁts for research continuity, clinical associations and
enhance progress to mainstream cell therapy.
In order for cell nomenclature to be informative, accurate and
biologically meaningful, we propose that it should describe two
interrelated characteristics: a speciﬁc phenotype and a biological
function. On these lines, for the two distinct EPC subtypes isolated
in culture, we support the terminology ECFCs [25] and MACs [19]
because they accurately describe the phenotype and function of
these cell-types. We do not support the use of the term EPCs
because of its intrinsic ambiguity. In particular, EPCs should not be
used to name cells such as MACs/CACs because these cells are
not endothelial nor progenitor cells [23], but myeloid cells, albeit
with potent pro-angiogenic, vasoreparative functionality [26–28],
through a paracrine mechanism [29]. It is important to highlight
that MACs do not give rise to endothelial cells, but remain true to
their hematopoietic nature [17, 19]. Ideally the term endothelial
progenitor, if ever used to describe a population of cells, should
be strictly reserved for cells with an endothelial phenotype, self-
renewal potential, and capacity for de novo, in vivo blood vessel
formation.
While discrepancies in the ﬁeld may be inevitable, standar-
dized tests such as potency assays are required to harmonize
standards and improve accuracy. In this context, endothelial
behavior such as the capacity to form a vascular network in vitro
and in vivo, coupled with a detailed identity immunophenotype,
should be used as routine standards during cell characterization.
In addition, clonogenicity and proliferative capacity should
become standard criteria to distinguish true progenitors from
mature endothelial cells. Based on the collective experience in
the authors’ laboratories, the minimum requirements for an ECFC
are: unequivocal endothelial cell phenotype, signiﬁcant prolifera-
tive potential, and capacity to self-assemble into functional blood
vessels in vivo. We operationally deﬁned ECFCs as cultured cells
derived from umbilical cord blood or peripheral blood mononu-
clear cells, grown under endothelial cell culture conditions, which
are characterized by an immunophenotype depicted as positive
for CD31, VE-Cadherin, von Willebrand factor, CD146, VEGFR2,
and importantly negative for CD45 and CD14 [30–32]. These cells
also express CD34, although expression level of this antigen may
decline during in vitro expansion. Functionally, ECFC must exhibit
Figure 2. Cell types studied for their pro-angiogenic properties. Complex nomenclature can be divided into two distinct groups according
to phenotypic lineage: hematopoietic and endothelial. Table provides minimal criteria to deﬁne MACs and ECFCs based on immunopheno-
type, including negative markers for purity; and function, assessed as a potency assay. Abbreviations: BOECs, blood outgrowth endothelial
cells; CACs, circulating angiogenic cells’; CFU, colony forming unit; ECFCs, endothelial colony forming cells; OECs, endothelial outgrowth cells;
EPC, endothelial progenitor cell; MACs, myeloid angiogenic cells; PACs, pro-angiogenic hematopoietic cells.
1318 Endothelial Progenitors Nomenclature
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
signiﬁcant proliferative capacity and possess vascular network
forming potential in vitro and in vivo.
NEXT GENERATION ENDOTHELIAL PROGENITORS
Thanks to advances in cell characterization methodologies and
technologies, we are starting to recover and identify cell subpo-
pulations within homogenous cell populations such as ECFCs. For
example, well-deﬁned hierarchies based on ECFC proliferative
potential and in vivo vasculogenic activity have been described
[30, 33]. Similarly, it has been reported that ECFCs can be classi-
ﬁed according to aldehyde dehydrogenase (Alde) activity [34]
with low-Alde levels being associated with higher reparative
capacities in ischemic tissues than high-Alde ECFCs. Such studies
provide enhanced precision in the ﬁeld, and further advance-
ments in technology such as ﬂow cytometry, cell sorting, and sin-
gle cell genomics will facilitate ever-improving understanding of
endothelial progenitor biology. As an example, using induced plu-
ripotent stem cell (iPSC) technology, protocols have been
designed for differentiation of human iPSCs into ECFCs [35],
which may allow detailed investigation into molecular mecha-
nisms driving endothelial differentiation. Characterization of ECFC
pro-angiogenic activity has signiﬁcant translational potential
because such functionality can be used as a surrogate marker for
personalized medicine [36, 37].
While bone marrow is considered the classical source for endo-
thelial progenitors, emerging evidence supports the existence of
vascular progenitor cells which are resident in various organs [38]
and carry signiﬁcant vascular homeostatic and regeneration capacity
[39]. For example, it has been suggested that the endothelial lining
of blood vessels is a major source of ECFCs, and a complete hierar-
chy of ECFCs based on single cell clonogenic capacity has been iden-
tiﬁed in endothelial cultures from umbilical vein and aorta [40].
ECFCs have also been isolated from human placenta [41] and
human white adipose tissue [42]. In addition, a “vasculogenic zone”
within the vascular wall has also been reported to contain endothe-
lial precursors and multipotent mesodermal stem cells [43]. Future
research into deﬁning the precise tissue niche of true endothelial
progenitors in vivo is warranted [44]. Likewise, it is important to
determine if there is organ-speciﬁcity for progenitors as this has
been demonstrated for microvascular endothelial cells [45]. Deter-
mining the niche where progenitors reside will provide further
important information to guide nomenclature.
Future research optimizing and improving methodology for
ECFC isolation and expansion in vitro coupled with transferring
academic laboratory protocols to GMP grade standard operating
procedures will facilitate translation of preclinical research into
clinical trials. Examples of these recent advances are the develop-
ment of a microﬂuidic system to capture ECFCs from human adult
peripheral blood [46]; and the replacement of FBS with human
platelet lysate for ECFC culture [47, 48]. Strategies to enhance
ECFC vasculogenic potential when delivered into ischemic tissues
are also being investigated [49, 50].
CONCLUSION
Accurate cell deﬁnitions represent a critical barrier for translation
of cell therapies into the clinic. Indeed, identity and purity are
essential requirements to deﬁne any cell therapy product. The
working deﬁnition for EPCs, as cells from circulating blood that
promote new blood vessel formation is not sufﬁciently accurate
in the era of precision medicine. This is especially true as our ﬁeld
progresses toward clinical use of efﬁcacious cell therapy products
[51], which require a detailed phenotypic identity, a measurement
of purity, and consistent functional readouts as minimal essential
release criteria. We believe that biologists working in the endo-
thelial progenitor ﬁeld should seek to align with these basic
requirements, not just to aid future clinical application, but to
help advance our basic scientiﬁc knowledge of these important
cells. Therefore, we endorse the terms ECFCs and MACs as well-
deﬁned cell populations isolated in culture with potential for ther-
apeutic angiogenesis.
ACKNOWLEDGMENTS
R.J.M. was supported by the Juvenile Diabetes Research Foun-
dation, Fight for Sight, the Leverhulme Trust, and the National
Eye Research Centre. K.K. was supported by the Australian
National Health and Medical Research Council (NHMRC). M.C.Y.
was partially supported by the National Institutes of Health
Grant DK106846 and the Riley Children’s Foundation. A.W.S.
was supported by the Sir Jules Thorn Trust, Fight for Sight, and
Invest Northern Ireland.
AUTHORS CONTRIBUTIONS
R.J.M., C.L.B., F.S., F.D.-G., J.M.M.-M., K.K., O.O., A.M.R., J.K.Y.C.,
T.Y., V.W.M.V.H., M.C.Y., and A.W.S.: conception and design, manu-
script writing, ﬁnal approval of manuscript; R.J.M. and T.Y.: ﬁgures
design.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
K.K. is an inventor on a patent licenced to AngioStem. The other
authors indicated no potential conﬂicts of interest.
REFERENCES
1 Basile DP, Yoder MC. Circulating and tis-
sue resident endothelial progenitor cells.
J Cell Physiol 2014;229:10–16.
2 Yoder MC, Mead LE, Prater D et al. Rede-
ﬁning endothelial progenitor cells via clonal
analysis and hematopoietic stem/progenitor
cell principals. Blood 2007;109:1801–1809.
3 Purhonen S, Palm J, Rossi D et al. Bone
marrow-derived circulating endothelial pre-
cursors do not contribute to vascular endothe-
lium and are not needed for tumor growth.
Proc Natl Acad Sci USA 2008;105:6620–6625.
4 Barber CL, Iruela-Arispe ML. The ever-
elusive endothelial progenitor cell: Identities,
functions and clinical implications. Pediatr Res
2006;59:26R–32R.
5 Prokopi M, Pula G, Mayr U et al. Proteo-
mic analysis reveals presence of platelet
microparticles in endothelial progenitor cell
cultures. Blood 2009;114:723–732.
6 Kim SJ, Kim JS, Papadopoulos J et al. Cir-
culating monocytes expressing CD31: Implica-
tions for acute and chronic angiogenesis. Am J
Pathol 2009;174:1972–1980.
7 Asahara T, Murohara T, Sullivan A et al.
Isolation of putative progenitor endothelial
cells for angiogenesis. Science 1997;275:964–
967.
8 Medina RJ, O’Neill CL, O’Doherty TM et al.
Endothelial progenitors as tools to study vascu-
lar disease. Stem Cells Int 2012;2012:346735.
9 Peichev M, Naiyer AJ, Pereira D et al.
Expression of VEGFR-2 and AC133 by circulat-
ing human CD34(1) cells identiﬁes a popula-
tion of functional endothelial precursors.
Blood 2000;95:952–958.
10 Werner N, Kosiol S, Schiegl T et al. Cir-
culating endothelial progenitor cells and cardi-
ovascular outcomes. N Engl J Med 2005, 353:
999–1007.
Medina, Barber, George et al. 1319
www.StemCellsTM.com Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
11 Wu X, Lensch MW, Wylie-Sears J et al.
Hemogenic endothelial progenitor cells iso-
lated from human umbilical cord blood. STEM
CELLS 2007;25:2770–2776.
12 Case J, Mead LE, Bessler WK et al.
Human CD341AC1331VEGFR-21 cells are
not endothelial progenitor cells but distinct,
primitive hematopoietic progenitors. Exp
Hematol 2007;35:1109–1118.
13 Yoon CH, Hur J, Park KW et al. Synergis-
tic neovascularization by mixed transplanta-
tion of early endothelial progenitor cells and
late outgrowth endothelial cells: The role of
angiogenic cytokines and matrix metallopro-
teinases. Circulation 2005;112:1618–1627.
14 Medina RJ, O’Neill CL, Sweeney M
et al. Molecular analysis of endothelial pro-
genitor cell (EPC) subtypes reveals two distinct
cell populations with different identities. BMC
Med Genomics 2010;3:18.
15 Asahara T, Kawamoto A, Masuda H.
Concise review: Circulating endothelial pro-
genitor cells for vascular medicine. STEM CELLS
2011;29:1650–1655.
16 Vaughan EE, O’Brien T. Isolation of cir-
culating angiogenic cells. Methods Mol Biol
2012;916:351–356.
17 O’Neill CL, Guduric-Fuchs J, Chambers
SE et al. Endothelial cell-derived Pentraxin 3
limits the vasoreparative therapeutic potential
of circulating angiogenic cells. Cardiovasc Res
2016;112:677–688
18 Stitt AW, O’Neill CL, O’Doherty MT
et al. Vascular stem cells and ischaemic retino-
pathies. Prog Retin Eye Res 2011;30:149–166.
19 Medina RJ, O’Neill CL, O’Doherty TM
et al. Myeloid angiogenic cells act as alterna-
tive M2 macrophages and modulate angio-
genesis through interleukin-8. Mol Med 2011;
17:1045–1055.
20 Lin Y, Weisdorf DJ, Solovey A et al. Ori-
gins of circulating endothelial cells and endo-
thelial outgrowth from blood. J Clin Invest
2000;105:71–77.
21 Tasev D, Koolwijk P, van Hinsbergh VW.
Therapeutic potential of human-derived endo-
thelial colony-forming cells in animal models.
Tissue Eng Part B Rev 2016;22:371–382.
22 Lin RZ, Moreno-Luna R, Li D et al.
Human endothelial colony-forming cells serve
as trophic mediators for mesenchymal stem
cell engraftment via paracrine signaling. Proc
Natl Acad Sci USA 2014;111:10137–10142.
23 Pearson JD. Endothelial progenitor
cells–an evolving story. Microvasc Res 2010;
79:162–168.
24 Murasawa S, Asahara T. Endothelial
progenitor cells for vasculogenesis. Physiology
(Bethesda) 2005;20:36–42.
25 Prasain N, Meador JL, Yoder MC. Phe-
notypic and functional characterization of
endothelial colony forming cells derived from
human umbilical cord blood. J Vis Exp 2012;
62:3872.
26 Chambers SE, O’Neill CL, O’Doherty TM
et al. The role of immune-related myeloid cells
in angiogenesis. Immunobiology 2013;218:
1370–1375.
27 Kanayasu-Toyoda T, Tanaka T, Kikuchi Y
et al. Cell-surface MMP-9 protein is a novel
functional marker to identify and separate
proangiogenic cells from early endothelial
progenitor cells derived from CD133(1) cells.
STEM CELLS 2016;34:1251–1262.
28 Urbich C, Heeschen C, Aicher A et al.
Relevance of monocytic features for neovascu-
larization capacity of circulating endothelial
progenitor cells. Circulation 2003;108:2511–
2516.
29 Urbich C, Aicher A, Heeschen C et al.
Soluble factors released by endothelial pro-
genitor cells promote migration of endothelial
cells and cardiac resident progenitor cells.
J Mol Cell Cardiol 2005;39:733–742.
30 Ingram DA, Mead LE, Tanaka H et al.
Identiﬁcation of a novel hierarchy of endothe-
lial progenitor cells using human peripheral
and umbilical cord blood. Blood 2004;104:
2752–2760.
31 Medina RJ, O’Neill CL, O’Doherty TM
et al. Ex vivo expansion of human outgrowth
endothelial cells leads to IL-8-mediated repli-
cative senescence and impaired vasorepara-
tive function. STEM CELLS 2013;31:1657–1668.
32 Poitevin S, Cussac D, Leroyer AS et al.
Sphingosine kinase 1 expressed by endothelial
colony-forming cells has a critical role in their
revascularization activity. Cardiovasc Res
2014;103:121–130.
33 Patel J, Wong HY, Wang W et al. Self-
renewal and high proliferative colony forming
capacity of late-outgrowth endothelial pro-
genitors is regulated by cyclin-dependent
kinase inhibitors driven by notch signaling.
STEM CELLS 2016;34:902–912.
34 Nagano M, Yamashita T, Hamada H
et al. Identiﬁcation of functional endothelial
progenitor cells suitable for the treatment of
ischemic tissue using human umbilical cord
blood. Blood 2007;110:151–160.
35 Prasain N, Lee MR, Vemula S et al. Dif-
ferentiation of human pluripotent stem cells
to cells similar to cord-blood endothelial
colony-forming cells. Nat Biotechnol 2014;32:
1151–1157.
36 Reed DM, Paschalaki KE, Starke RD
et al. An autologous endothelial cell: Periph-
eral blood mononuclear cell assay that detects
cytokine storm responses to biologics. FASEB J
2015;29:2595–2602.
37 Paschalaki KE, Starke RD, Hu Y et al.
Dysfunction of endothelial progenitor cells
from smokers and chronic obstructive pulmo-
nary disease patients due to increased DNA
damage and senescence. STEM CELLS 2013;31:
2813–2826.
38 Torsney E, Xu Q. Resident vascular pro-
genitor cells. J Mol Cell Cardiol 2011;50:304–
311.
39 Khmelewski E, Becker A, Meinertz T
et al. Tissue resident cells play a dominant
role in arteriogenesis and concomitant
macrophage accumulation. Circ Res 2004;95:
E56–64.
40 Ingram DA, Mead LE, Moore DB et al.
Vessel wall-derived endothelial cells rapidly
proliferate because they contain a complete
hierarchy of endothelial progenitor cells.
Blood 2005;105:2783–2786.
41 Patel J, Seppanen E, Chong MS et al.
Prospective surface marker-based isolation
and expansion of fetal endothelial colony-
forming cells from human term placenta. STEM
CELLS TRANSL MED 2013;2:839–847.
42 Lin RZ, Moreno-Luna R, Munoz-
Hernandez R et al. Human white adipose
tissue vasculature contains endothelial
colony-forming cells with robust in vivo
vasculogenic potential. Angiogenesis 2013;
16:735–744.
43 Zengin E, Chalajour F, Gehling UM et al.
Vascular wall resident progenitor cells: A
source for postnatal vasculogenesis. Develop-
ment 2006;133:1543–1551.
44 Goligorsky MS, Salven P. Concise
review: Endothelial stem and progenitor cells
and their habitats. STEM CELLS TRANSL MED
2013;2:499–504.
45 Nolan DJ, Ginsberg M, Israely E et al.
Molecular signatures of tissue-speciﬁc micro-
vascular endothelial cell heterogeneity in
organ maintenance and regeneration. Dev Cell
2013;26:204–219.
46 Lin RZ, Hatch A, Antontsev VG et al.
Microﬂuidic capture of endothelial colony-
forming cells from human adult peripheral
blood: Phenotypic and functional validation in
vivo. Tissue Eng Part C Methods 2015;21:274–
283.
47 Kim H, Prasain N, Vemula S et al.
Human platelet lysate improves human cord
blood derived ECFC survival and vasculogene-
sis in three dimensional (3D) collagen matri-
ces. Microvasc Res 2015;101:72–81.
48 Tasev D, van Wijhe MH, Weijers EM
et al. Long-term expansion in platelet lysate
increases growth of peripheral blood-derived
endothelial-colony forming cells and their
growth factor-induced sprouting capacity.
PLoS One 2015;10:e0129935.
49 Stalin J, Harhouri K, Hubert L et al.
Soluble CD146 boosts therapeutic effect of
endothelial progenitors through proteolytic
processing of short CD146 isoform. Cardiovasc
Res 2016;111:240–251.
50 Goto K, Takemura G, Takahashi T
et al. Intravenous administration of endo-
thelial colony-forming cells overexpressing
integrin beta1 augments angiogenesis in
ischemic legs. STEM CELLS TRANSL MED 2016;
5:218–226.
51 Chong MS, Ng WK, Chan JK. Concise
review: Endothelial progenitor cells in regen-
erative medicine: Applications and challenges.
STEM CELLS TRANSL MED 2016;5:530–538.
1320 Endothelial Progenitors Nomenclature
Oc 2017 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
